中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
16期
1-2,3
,共3页
尿嘧啶替加氟%宫颈癌%维持化疗
尿嘧啶替加氟%宮頸癌%維持化療
뇨밀정체가불%궁경암%유지화료
Uracil-tegafur%Cervical cancer%Maintenance chemotherapy
目的：探讨Ⅱb~Ⅲ期宫颈癌同期放化疗后口服尿嘧啶替加氟维持化疗的疗效及不良反应。方法85例Ⅱb~Ⅲ期宫颈癌患者，随机分为两组，其中维持化疗组40例，该组患者同期放化疗完成后给予口服尿嘧啶替加氟维持化疗至少1年，对照组45例仅随访观察。比较两组患者近期疗效及不良反应。结果维持化疗组无进展生存时间较对照组延长，中位无进展生存时间分别为32个月与27个月，差异有统计学意义(P=0.022<0.05)。两组骨髓抑制及胃肠道反应发生率比较，差异无统计学意义(P>0.05)。结论口服尿嘧啶替加氟维持化疗可改善Ⅱb~Ⅲ期宫颈癌生存质量，且未明显增加毒性反应，有望在临床上推广使用。
目的：探討Ⅱb~Ⅲ期宮頸癌同期放化療後口服尿嘧啶替加氟維持化療的療效及不良反應。方法85例Ⅱb~Ⅲ期宮頸癌患者，隨機分為兩組，其中維持化療組40例，該組患者同期放化療完成後給予口服尿嘧啶替加氟維持化療至少1年，對照組45例僅隨訪觀察。比較兩組患者近期療效及不良反應。結果維持化療組無進展生存時間較對照組延長，中位無進展生存時間分彆為32箇月與27箇月，差異有統計學意義(P=0.022<0.05)。兩組骨髓抑製及胃腸道反應髮生率比較，差異無統計學意義(P>0.05)。結論口服尿嘧啶替加氟維持化療可改善Ⅱb~Ⅲ期宮頸癌生存質量，且未明顯增加毒性反應，有望在臨床上推廣使用。
목적：탐토Ⅱb~Ⅲ기궁경암동기방화료후구복뇨밀정체가불유지화료적료효급불량반응。방법85례Ⅱb~Ⅲ기궁경암환자，수궤분위량조，기중유지화료조40례，해조환자동기방화료완성후급여구복뇨밀정체가불유지화료지소1년，대조조45례부수방관찰。비교량조환자근기료효급불량반응。결과유지화료조무진전생존시간교대조조연장，중위무진전생존시간분별위32개월여27개월，차이유통계학의의(P=0.022<0.05)。량조골수억제급위장도반응발생솔비교，차이무통계학의의(P>0.05)。결론구복뇨밀정체가불유지화료가개선Ⅱb~Ⅲ기궁경암생존질량，차미명현증가독성반응，유망재림상상추엄사용。
ObjectiveTo investigate the curative effect by oral administration of uracil-tegafur for maintenance chemotherapy of stageⅡb~Ⅲ cervical cancer after concurrent chemoradiotherapy.MethodsA total of 85 patients with stageⅡb~Ⅲ cervical cancer were randomly divided into two groups. Maintenance chemotherapy group with 40 cases received oral administration of uracil-tegafur for at least 1 year after concurrent chemoradiotherapy. Control group with 45 cases received follow-up alone. Short-term effects and adverse reactions of the two groups were compared.ResultsThe maintenance chemotherapy group had longer progression free survival than the control group, and their median progression free survival were respectively 32 months and 27 months. Their difference had statistical significance (P=0.022<0.05). There were no statistically significant differences of myelosuppression and incidence of gastrointestinal reactions between the two groups (P>0.05).ConclusionOral administration of uracil-tegafur can improve life quality in stage Ⅱb~Ⅲ cervical cancer, without any increased toxic reactions. This method is worthy of clinical promotion and application.
